Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EWING 2008 for newly diagnosed Ewing sarcoma
ACTRN12616001524482Phase 3Active, not recruiting
- Sponsor
- Universitätsmedizin Essen
- Start
- Aug 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of vincristine, ifosfamide, doxorubicin, etoposide, actinomycin D and 5 more in Ewing sarcoma and Ewing sarcoma of bone (7 arms), sponsored by Universitätsmedizin Essen. Primary endpoints: Event-free survival in standard-risk R1, Event-free survival in high-risk R2 and 2 more. Started Aug 2014; status: active, not recruiting.
02
Drugs
vincristineifosfamidedoxorubicinetoposideactinomycin D
03
Conditions
Ewing sarcomaEwing sarcoma of bone
Beyond the preview
Go deeper on ACTRN12616001524482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001524482.